Abstract

Background The aim of the current study is to cast further light on the issues related to prognostication of renal cell carcinoma (RCC), assessing the expression of survivin in a subset of primary RCC and determining its relation to different clinicopathological features and disease-free survival. Methods The present series consisted of tissue samples obtained from 37 Libyan patients with stage I, II, III, or IV RCC. Survivin expression in these tumours was assessed by immunohistochemistry using an automated staining system. Different grading systems were tested for expression of survivin. Findings Expression of survivin was significantly associated with venous invasion (tumour thrombus; p = 0.042), larger tumour size ( p = 0.051), higher primary T classification ( p = 0.013), advanced tumour stage ( p = 0.033), and borderline associated ( p = 0.068) with tumour location. In univariate Kaplan–Meier survival analysis, surviving expression showed a borderline association ( p = 0.089) with disease-free survival. However, there was no significant correlation between survivin expression and gender, age, histological grade, distance metastasis, lymph node involvement, perinephric fat and capsular invasion, status at end point and recurrence. Interpretation Survivin expression in RCC may identify patients at risk of a more aggressive disease and a worse prognosis. Further investigations, on a larger and more heterogeneous population, should be carried out to validate and extend our results.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.